FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.
You may also be interested in...
New Acting US FDA Commissioner Shares Agency's Clinical Trial Reform Message
Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.
Large Simple Trials Need FDA Boost, IoM Report Says
“Clear specific guidance” from the agency would help close the perception gap between what types of data industry thinks FDA wants and what the agency actually expects, according to a summary of a 2012 Institute of Medicine workshop.
FDA To Be More Vigilant About Proposed Clinical Trial Exclusions
FDA’s Bob Temple says “document” being drafted will instruct reviewers to pay more attention during sponsor meetings and eliminate unnecessary exclusions from protocols.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: